Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)

Limei Michelle Poon, Partow Kebriaei

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The treatment paradigm for acute lymphomablastic leukemia has been constantly changing. Historically, allogeneic transplantation (alloHCT) has been a mainstay in the treatment for adult ALL patients due to its effectiveness in preventing disease relapse and due to the poorer outcomes of adult ALL treatment protocols compared to pediatric patients. There have been ongoing advances in the treatment of ALL including the use of pediatric-like protocols as well as the incorporation of oncogenomics and MRD-based responses into prognostic models. In addition, in the last decade, there has been a rapid development of immune-based therapies, and three agents inotuzumab, blinatumomab, and chimeric antigenic T-cell therapy (CAR-T) have been approved for the treatment for relapsed ALL. In the field of alloHCT, the use of reduced intensity conditioning and alternative donor sources has improved the accessibility of alloHCT. In this chapter, we review the latest literature addressing these issues and discuss the relevance of alloHCT in this rapidly changing treatment landscape.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages193-204
Number of pages12
DOIs
StatePublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Keywords

  • Acute lymphoblastic leukemia
  • Allogeneic transplantation
  • Autologous transplantation
  • Novel immunotherapy
  • Ph negative

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)'. Together they form a unique fingerprint.

Cite this